Serum Calcitonin Levels may be Used in the Differential Diagnosis of Vagal Glomus
DOI:
https://doi.org/10.17140/OTLOJ-3-136Keywords:
Calcitonin, Medullary thyroid cancer, Glomus vagaleAbstract
Medullary thyroid carcinoma (MTC) is a neuroendocrine (NE) tumor and is very rarely ob-served. MTC originates from the parafolliculer C cell and can show various histopathological patterns. Head and neck paragangliomas are seen rarely. Paragangliomas in the head and neck region are usually non-functional. MTC should be considered in the differential diagnosis of paragangliomas in the head and neck region. A high degree of clinical investigation is needed to determine the rare potential etiology underlying this condition. Because patients with MTC can present different clinical manifestations, otolaryngologist must be aware of MTC and its rare medical presentations. This case presented here highlights the importance of serum calcitonin levels in the differential diagnosis of paragangliomas in the head and neck region.
References
Albores-Saavedra J, LiVolsi VA, Williams ED. Medullary car-cinoma. Semin Diagn Pathol. 1985; 2: 137-146.
Wells SA Jr., Franz C. Medullary carcinoma of the thy-roid gland. World J Surg. 2000; 24: 952-956. doi: 10.1007/ s002680010166
Matias-Guiu X, De Lellis R. Medullary thyroid carcinoma: A 25-year perspective. Endocr Pathol. 2014; 25: 21-29. doi: 10.1007/s12022-013-9287-2
Wells SA Jr., Pacini F, Robinson BG, Santoro M. Multiple en-docrine neoplasia type 2 and familial medullary thyroid carcino-ma: An update. J Clin Endocrinol Metab. 2013; 98: 3149-3164. doi: 10.1210/jc.2013-1204
Wells SA Jr., Asa SL, Dralle H, et al. Revised american th-yroid association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015; 25: 567-610. doi: 10.1089/ thy.2014.0335
Baloch ZW, LiVolsi VA. C-cells and their associated lesions and conditions: A pathologists perspective. Turk Patoloji Derg. 2015; 31: 60-79. doi: 10.5146/tjpath.2015.01315
Jung KY, Kim SM, Yoo WS, et al. Postoperative biochemical remission of serum calcitonin is the best predictive factor for re-currence-free survival of medullary thyroid cancer: A large-sca-le retrospective analysis over 30 years. Clin Endocrinol (Oxf). 2016; 84: 587-597. doi: 10.1111/cen.12852
Chernock RD, Hagemann IS. Molecular pathology of heredi-tary and sporadic medullary thyroid carcinomas. Am J Clin Pat-hol. 2015; 143: 768-777. doi: 10.1309/AJCPHWACTTUYJ7DD
Chen H, Sippel RS, O’Dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the di-agnosis and management of neuroendocrine tumors: Pheochro-mocytoma, paraganglioma, and medullary thyroid cancer. Panc-reas. 2010; 39: 775-783. doi: 10.1097/MPA.0b013e3181ebb4f0
Destito D, Bucolo S, Florio A, Quattrocchi C. Management of head and neck paragangliomas: A series of 9 cases and review of the literature. Ear Nose Throat J. 2012; 91(8): 366-375. Web site. http://search.proquest.com/openview/3e1d238ac459837089a-213989944ecd6/1?pq-origsite=gscholar&cbl=47886. Accessed January 7, 2017.
Canberk Ş, Fırat P, SchmItt F. Pitfalls in the cytological as-sessment of thyroid nodules. Turk Patoloji Derg. 2015; 31: 18- 33. doi: 10.5146/tjpath.2015.01312
Sivrikoz E, Ozbey NC, Kaya B, et al. Neuroendocrine tu-mors presenting with thyroid gland metastasis: A case series. J Med Case Rep. 2012; 6: 73. doi: 10.1186/1752-1947-6-73
Busnardo B, Girelli ME, Simioni N, Nacamulli D, Buset-to E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carci-noma. Cancer. 1984; 53: 278-285. doi: 10.1002/1097-0142 (19840115)53:2<278::AID-CNCR2820530216>3.0.CO;2-Z
Kloos RT, Eng C, Evans DB, et al. American thyroid associ-ation guidelines task force. Medullary thyroid cancer: Manage-ment guidelines of the American Thyroid Association. Thyroid. 2009; 19: 565-612. doi: 10.1089/thy.2008.0403
Aschebrook-Kilfoy B, Schechter RB, Shih YC, et al. The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol Biomarkers Prev. 2013; 22: 1252-1259. doi: 10.1158/1055-9965.EPI-13-0242
Oh CM, Jung KW, Won YJ, Shin A, Kong HJ, Lee JS. Age-period-cohort analysis of thyroid cancer incidence in Korea. Cancer Res Treat. 2015; 47: 362-369. doi: 10.4143/crt.2014.110
Lindsey SC, Ganly I, Palmer F, Tuttle RM. Response to initial therapy predicts clinical outcomes in medullary thyroid cancer. Thyroid. 2015; 25: 242-249. doi: 10.1089/thy.2014.0277
Schlumberger M, Elisei R, Muller S, et al. Final overall survival analysis of EXAM, an international, double-blind, randomized, placebo-controlled phase III trial of cabozantinib (Cabo) in medullary thyroid carcinoma (MTC) patients with do-cumented RECIST progression at baseline. J Clin Oncol. 2015; 33(15 Suppl): S6012. Web site. http://meetinglibrary.asco.org/ content/147994-156. Accessed January 7, 2017.
Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: Clinical characteristics, treat-ment, prognostic factors, and a comparison of staging systems. Cancer. 2000; 88: 1139-1148.
Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on tre-atment of clinical and pathologic variables. Cancer. 1996; 77: 1556-1565. doi: 10.1002/(SICI)1097-0142(19960415)77:8<155 6::AID-CNCR20>3.0.CO;2-Y
Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carci-noma: Results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol (Oxf). 1998; 48: 265-273. doi: 10.1046/j.1365-2265.1998.00392.x
Figlioli G, Landi S, Romei C, Elisei R, Gemignani F. Me-dullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat Res. 2013; 752: 36-44. doi: 10.1016/j.mrrev.2012.09.002
Raue F, Kotzerke J, Reinwein D, et al. Prognostic factors in medullary thyroid carcinoma: Eevaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Inves-tig. 1993; 71: 7-12. doi: 10.1007/BF00210956
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Otolaryngology (OOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
